The Xpert Carba-R Assay, developed by Sunnyvale, Calif.-based Cepheid, is intended to serve as an aid in infection control. The tool tests for the most prevalent genes associated with resistance to the carbapenem antibiotics, but does not detect the bacteria itself or other possible causes of carbapenem resistance.
Current methods to identify the resistant organisms entail growing bacteria from fecal material in cultures and then subjecting the samples to antimicrobial susceptibility testing, a process that can take up to four days.
“By using a specimen taken directly from a patient to test for the presence of genetic markers, hospitals can more quickly identify these dangerous bacteria resistant to certain antibiotics,” said Alberto Gutierrez, MD, director of the FDA’s Office of In Vitro Diagnostics and Radiological Health.
More articles on supply chain:
German researchers test ‘universal cancer vaccine’
6 New Jersey, Pennsylvania health systems form GPO
How 4 startups redesigned the breast pump
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
